KISQALI
As listed in the register: KISQALI
200 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ribociclib (Ribociclib Succinate)
- Made by
- Novartis Pharmaceuticals Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain3 matching products
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Novartis Pharmaceuticals Canada Inc |
|---|---|
| Active substance | Ribociclib (Ribociclib Succinate) |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 200 mg |
| Form | tablet |
| Classification | L01EF02 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02473569 |
| DPD drug code | 96295 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.